Danaher completes acquisition of Masimo

Masimo
Danaher Corporation

Masimo

MASI

0.00

Danaher Corporation

DHR

0.00
  • Danaher completed its acquisition of Masimo, making the patient-monitoring specialist a wholly owned subsidiary.
  • Masimo shares stopped trading on Nasdaq.
  • Masimo will keep its brand, operating as a stand-alone company within Danaher’s Diagnostics segment.
  • Danaher kept its Q2 and full-year 2026 guidance unchanged, excluding Masimo’s contribution.
  • Masimo is not expected to contribute materially in Q2 2026; full-year guidance update planned with Q2 earnings.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Danaher Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606100855PR_NEWS_USPR_____PH80531) on June 10, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.